Zenith Capital Corp.

Equities

ZHCLF

CA98935N1033

Market Closed - OTC Markets Other stock markets 01:33:54 2024-04-24 pm EDT			5-day change	1st Jan Change
0.2 ^USD	-13.04%		0.00%	+66.67%

Apr. 05	Zenith Capital Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	CI
2023	Zenith Capital Corp. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	CI

Zenith Capital Corp. announced that it has received $5.000001 million in funding from Newsoara BioPharma Co., Ltd.

September 07, 2020

On September 8, 2020, Zenith Capital Corp. (OTCPK:ZHCL.F) closed the transaction. The company has issued 1,333,333 shares for gross proceeds of $2,000,000 in its fourth and final tranche.

Latest news about Zenith Capital Corp.

Zenith Capital Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Apr. 05	CI
Zenith Capital Corp. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	Dec. 22	CI
Zenith Capital Corp. Reports Earnings Results for the First Quarter Ended July 31, 2023	23-09-27	CI
Zenith Capital Corp. Reports Earnings Results for the Full Year Ended April 30, 2023	23-08-28	CI
Zenith's Bet Inhibitor ZEN-3694 Providing Significant Clinical Benefit in Patients with Aggressive Cancer Type	23-06-01	CI
Zenith Capital Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023	23-04-06	CI
Zenith Capital Corp. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022	22-12-23	CI
Zenith Capital Corp. Reports Earnings Results for the First Quarter Ended July 31, 2022	22-09-29	CI
Zenith Capital Corp. Auditor Raises 'Going Concern' Doubt	22-09-14	CI
Zenith Capital Corp. Reports Earnings Results for the Full Year Ended April 30, 2022	22-09-14	CI
Zenith Epigenetics Announces Initiation of Phase 2b Triple Negative Breast Cancer Clinical Trial	22-05-10	CI
Zenith Capital Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2022	22-03-31	CI
Zenith Epigenetics Provides Clinical Update	22-01-31	CI
Zenith Epigenetics Announces Changes to Board of Directors	22-01-31	CI
Zenith Capital Corp. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2021	21-12-20	CI
Newsoara BioPharma Co., Ltd. announced that it expects to receive $1.5 million in funding from Zenith Capital Corp.	21-11-14	CI
Zenith Capital Corp. Reports Earnings Results for the Full Year Ended April 30, 2021	21-08-30	CI
Zenith Capital Corp. Auditor Raises 'Going Concern' Doubt	21-08-29	CI
Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metastatic Castration-Resistant Prostate Cancer	21-06-24	CI
Zenith Epigenetics Announces Clinical Collaboration with Astellas	21-04-22	CI
Zenith Capital Corp. Reports Earnings Results for the Third Quarter Ended January 31, 2021	21-04-06	CI
Zenith Epigenetics Announces Dosing of First Mcrpc Patient with A Combination of Zen-3694 + Merck's Immune Check Point Inhibitor Keytruda	21-03-15	CI
Zenith Capital Corp. Auditor Raises 'Going Concern' Doubt	20-10-08	CI
Zenith Epigenetics Announces Collaboration with Nci in Developing Zen-3694 for Multiple Oncology Indications	20-10-05	CI
Zenith Capital Corp. announced that it has received $5.000001 million in funding from Newsoara BioPharma Co., Ltd.	20-09-07	CI

Chart Zenith Capital Corp.

Duration

Period

More charts

Company Profile

Sector

Calendar

2024-08-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data